Combining two anti-HER2 drugs improves outcomes more effectively than one
https://www.facingourrisk.org/XRAY/combining-anti-HER2-drugs-improves-outcomes
Full article: https://atgproductions.net/atgclients/sabcs/2023_SABCS_Abstract_Report-12-3-23.pdf#xd_co_f=NWRmYmU4NGMtMzljMC00OTYyLWFmM2QtMDgyYmY2ZDA5ZWM3~
Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Is Tukysa plus Kadcyla a treatment option for my type of breast cancer?
- If it is not an option for me now, might it be a future option?
- If I have serious side effects, will I need to stop treatment?
- Are any other drugs available to treat my cancer?
Open Clinical Trials
The following studies look at treatment for people with metastatic HER2-positive breast cancer:
- NCT05458674: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC. This study evaluates the safety and efficacy of combining the drugs tucatinib, trastuzumab and eribulin in patients with unresectable metastatic HER2-positive breast cancer after prior treatment with a taxane, trastuzumab and T-DM1.
- NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN). This study evaluates the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta or trastuzumab biosimilar) in metastatic HER2+ breast cancer.
- NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer. This study evaluates the safety and effectiveness of zanidatamab combined with chemotherapy compared to trastuzumab (Herceptin) combined with chemotherapy to treat participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous T-DXd treatment.
- NCT05378464: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer. This study tests the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) vaccine given in combination with pepinemab added to standard-of-care therapy trastuzumab for people with HER2-positive breast cancer.
- NCT05894239: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer. This study looks at the safety and effectiveness of inavolisib combined with Phesgo (pertuzumab, trastuzumab and rHuPH20 injection) compared with a placebo combined with Phesgo for maintenance therapy after induction therapy for participants with previously untreated HER2-positive advanced breast cancer.
Other clinical trials for people with breast cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.